R547 is a potent and selective ATP-competitive CDK inhibitor.In cell-free assays, R547 effectively inhibited CDK1/cyclin B, CDK2/cyclin E, and CDK4/cyclin D1 (Ki = 1–3 nmol/L) and was inactive (Ki > 5,000 nmol/L) against a panel of >120 unrelated kinases. In vitro, R547 effectively inhibited the proliferation of tumor cell lines independent of multidrug resistant status, histologic type, retinoblastoma protein, or p53 status, with IC50s ≤ 0.60 μmol/L.
|Source||Oncogene (2012). Figure 6. R547|
|Cell Lines||p27−/− male mice|
|Incubation Time||13 day|
|Results||Strikingly, R547 reduced dysplasia (Figure 6D) and also modestly reduced ectopic mitoses but had no effect on progenitor mitoses that are distant or adjacent to phalloidin-marked apical membranes, respectively|
|Cell lines||human tumor cell lines HCT116, H460a, MDA-MB-435, DU145, LOX, and A549|
|Preparation method||Tetrazolium Dye Proliferation [3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide] Assay|
|Incubation time||48 h|
|Animal models||HCT116, H460a, MDA-MB-435, DU145, LOX, and A549|
|Formulation||Oral R547 was formulated as a suspension in Klucel LF/Tween 80, and i.v. R547 was formulated as a solution in hydroxylpropyl β-cyclodextrin, sodium hydroxide, and water for i.v. injection|
|Dosages||40 mg/kg daily oral dosing and 40 mg/kg i.v. once weekly|
|Administration||oral or i.v.|
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.
Assessment of network perturbation amplitudes by applying high-throughput data to causal biological networks.
Martin et al. BMC Syst Biol. 2012 May 31;6:54. PMID: 22651900.
Constitutive Smad linker phosphorylation in melanoma: a mechanism of resistance to transforming growth factor-β-mediated growth inhibition.
Cohen-Solal et al. Pigment Cell Melanoma Res. 2011 Jun;24(3):512-24. PMID: 21477078.
In vitro and in vivo activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials.
DePinto et al. Mol Cancer Ther. 2006 Nov;5(11):2644-58. PMID: 17121911.
Discovery of [4-Amino-2-(1-methanesulfonylpiperidin-4-ylamino)pyrimidin-5-yl](2,3-difluoro-6- methoxyphenyl)methanone (R547), a potent and selective cyclin-dependent kinase inhibitor with significant in vivo antitumor activity.
Chu et al. J Med Chem. 2006 Nov 2;49(22):6549-60. PMID: 17064073.
|Related CDK Products|
BSJ-03-123 is a potent and novel CDK6-selective small-molecule degrader.
THZ2 (an analog of THZ1) is a potent and selective CDK7 inhibitor which overcomes the instability of THZ1 in vivo (IC50s: CDK7=13.9 nM; TNBC cells=10 nM).
LY-3177833 is a potent and selective inhibitor of CDC7 with IC50 of 3.3 nM.
Voruciclib (P1446A-05) is a protein kinase inhibitor specific for the cyclin-dependent kinase 4 (CDK4) with IC50s of 90nM, 25nM, and 22nM for CDK4-CyclinD1, CDK1-Cyclin B, and CDK9-Cyclin T, respectively.
CVT-313 is a potent and selective inhibitor of CDK2 that prevents neointimal proliferation, which has an IC50 of 0.5 microM in vitro.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2017 AbMole BioScience. All Rights Reserved.